Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Enterobacterial Infections Clear all
Completed No phase listed Observational

Community-associated Highly-Resistant Enterobacterales

NCT03924934
View directory record Official record
Conditions
Enterobacteriaceae Infections, Community-Acquired Infections, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
2,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 28, 2026, 7:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

NCT02391909
View directory record Official record
Conditions
Typhoid Fever
Interventions
Vivotif
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

NCT01509846
View directory record Official record
Conditions
Shigellosis
Interventions
Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses, Placebo: 1-3 doses
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

NCT02388009
View directory record Official record
Conditions
Shigellosis
Interventions
Flexyn2a, Placebo, Flexyn2a plus adjuvant
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Sep 28, 2026, 7:19 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

NCT06258551
View directory record Official record
Conditions
Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

NCT04543877
View directory record Official record
Conditions
Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
Interventions
Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
Dietary Supplement · Biological
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 7:19 AM EDT
Completed No phase listed Observational

Antibiotic Resistant Community-Acquired E. Coli

NCT00298103
View directory record Official record
Conditions
E Coli Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Shigella Vaccine and Challenge

NCT04242264
View directory record Official record
Conditions
Immunisation, Shigella Infection
Interventions
Placebo, Shigella sonnei strain 53G, WRSs2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Decatur, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

NCT05138822
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Interventions
GSK3882347, Nitrofurantoin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Anniston, Alabama • Lomita, California • Modesto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 28, 2026, 7:19 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

NCT03040687
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 28, 2026, 7:19 AM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

NCT04574596
View directory record Official record
Conditions
E Coli Infection
Interventions
no Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
300 participants
Timeline
2020 – 2021
U.S. locations
13
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654
View directory record Official record
Conditions
Typhoid Fever
Interventions
Ty800 (Salmonella typhi) Oral Vaccine
Biological
Lead sponsor
Avant Immunotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2008 · Synced Sep 28, 2026, 7:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

NCT03548064
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli, Immunisation
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 28, 2026, 7:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Blood Donor CVD 5000

NCT03971669
View directory record Official record
Conditions
Risk Reduction
Interventions
Vivotif Typhoid Oral Vaccine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

NCT00097396
View directory record Official record
Conditions
Pneumonic Plague, Preventive Therapy
Interventions
rF1V vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

NCT00246467
View directory record Official record
Conditions
Plague
Interventions
Alhydrogel, rF1 and rV protein antigens
Biological
Lead sponsor
PharmAthene UK Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
9
States / cities
Huntsville, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

NCT05506969
View directory record Official record
Conditions
Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
Interventions
rF1V-1018, rF1V vaccine
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

NCT01382095
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Sep 28, 2026, 7:19 AM EDT
Completed No phase listed Observational

NCCLS Interpretive Criteria for Salmonella

NCT00177658
View directory record Official record
Conditions
Salmonella Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 28, 2026, 7:19 AM EDT
Completed No phase listed Observational

Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli

NCT00573235
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 28, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

NCT02816346
View directory record Official record
Conditions
Healthy
Interventions
Shigella sonnei 53G
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 28, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

NCT07049159
View directory record Official record
Conditions
Shigella
Interventions
ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Biological · Other
Lead sponsor
Eveliqure Biotechnologies GmbH
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 28, 2026, 7:19 AM EDT